Status:
COMPLETED
Bone Health in Patients With Atopic Dermatitis
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
Pediatric Dermatology Research Alliance
Conditions:
Atopic Dermatitis
Eczema
Eligibility:
All Genders
5-17 years
Brief Summary
This study examines the bone health in children with atopic dermatitis
Detailed Description
The goal of this study is to objectively evaluate bone health and contributing factors in children with AD. This will be compared with existing normative data. Such an objective prospective study, dir...
Eligibility Criteria
Inclusion
- Children 5 to 17 years of age with a diagnosis of moderate to severe atopic dermatitis as made by a dermatologist
- Duration of atopic dermatitis symptoms for a minimum of 6 months
- Ability to cooperate with DXA and HR-pQCT procedure
Exclusion
- Those without a confirmed diagnosis of moderate to severe atopic dermatitis
- Presence of concurrent disease that may also affect bone health, including rickets or other vitamin D deficiency, thyroid disease, renal disease, Paget's disease, osteogenesis imperfecta, inflammatory bowel disease, and other chronic inflammatory diseases
- Current use of medications that may affect bone health, including bisphosphonate, Forteo, Tymlos, denosumab, thiazide, heparin, medroxyprogesterone acetate, cyclosporine, and oral tacrolimus. However, medications that are used for atopic dermatitis treatment are allowed
- Pregnant or breast feeding females
- Inability to cooperate with the blood draw
Key Trial Info
Start Date :
July 30 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 16 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03800004
Start Date
July 30 2018
End Date
July 16 2024
Last Update
February 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55906